tiprankstipranks
Vertex Pharmaceuticals Inc. (VRTX)
NASDAQ:VRTX
US Market
VRTX
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

6,651 Followers
See the Price Targets and Ratings of:

VRTX Analyst Ratings

Strong Buy
24Ratings
Strong Buy
21 Buy
3 Hold
0 Sell
Based on 24 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$557.05
▲(28.63% Upside)
Based on 24 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $557.05 with a high forecast of $641.00 and a low forecast of $441.00. The average price target represents a 28.63% change from the last price of $433.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"400":"$400","521":"$521","642":"$642","460.5":"$460.5","581.5":"$581.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":641,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$641.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":557.0454545454545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$557.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":441,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$441.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[400,460.5,521,581.5,642],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,486.03,497.9507692307692,509.8715384615384,521.7923076923076,533.7130769230769,545.6338461538461,557.5546153846153,569.4753846153847,581.3961538461539,593.3169230769231,605.2376923076923,617.1584615384616,629.0792307692308,{"y":641,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,486.03,491.4927272727272,496.95545454545453,502.4181818181818,507.8809090909091,513.3436363636363,518.8063636363636,524.2690909090909,529.7318181818182,535.1945454545454,540.6572727272727,546.12,551.5827272727272,{"y":557.0454545454545,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,486.03,482.56615384615384,479.10230769230765,475.6384615384615,472.1746153846154,468.7107692307692,465.24692307692305,461.7830769230769,458.3192307692308,454.8553846153846,451.39153846153846,447.9276923076923,444.46384615384613,{"y":441,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":479.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":472.01,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":486.03,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$641.00Average Price Target$557.05Lowest Price Target$441.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on VRTX
Evan Seigerman
BMO Capital
BMO Capital
$600
Buy
38.55%
Upside
Reiterated
03/27/26
Vertex Pharmaceuticals: Resilient CF Franchise and Advancing Pipeline Support Buy Rating Despite Label Headwinds
William Blair Analyst forecast on VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Vertex Pharmaceuticals (NASDAQ: VRTX), Pacira Pharmaceuticals (NASDAQ: PCRX) and Alnylam Pharma (NASDAQ: ALNY)
Stifel Nicolaus Analyst forecast on VRTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$466
Hold
7.60%
Upside
Assigned
03/25/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Sarepta Therapeutics (NASDAQ: SRPT)
RBC Capital Analyst forecast on VRTX
Brian Abrahams
RBC Capital
RBC Capital
$546→$541
Buy
24.92%
Upside
Reiterated
03/19/26
RBC Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on VRTX
Naz Rahman
Maxim Group
Maxim Group
$575
Buy
32.77%
Upside
Upgraded
03/18/26
Vertex Pharmaceuticals upgraded to Buy from Hold at MaximVertex Pharmaceuticals upgraded to Buy from Hold at Maxim
Bank of America Securities Analyst forecast on VRTX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
03/16/26
Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)
Truist Financial Analyst forecast on VRTX
Joon Lee
Truist Financial
Truist Financial
$490→$525
Buy
21.23%
Upside
Reiterated
03/11/26
Vertex Pharmaceuticals price target raised to $525 from $490 at TruistVertex Pharmaceuticals price target raised to $525 from $490 at Truist
Canaccord Genuity Analyst forecast on VRTX
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$441
Hold
1.83%
Upside
Reiterated
03/11/26
Canaccord Genuity Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Analyst forecast on VRTX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$591→$641
Buy
48.01%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $641 from $591 at H.C. WainwrightVertex Pharmaceuticals price target raised to $641 from $591 at H.C. Wainwright
Needham Analyst forecast on VRTX
Joseph Stringer
Needham
Needham
$460
Hold
6.22%
Upside
Reiterated
03/10/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Oppenheimer Analyst forecast on VRTX
Jay Olson
Oppenheimer
Oppenheimer
$540→$600
Buy
38.55%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $600 from $540 at OppenheimerVertex Pharmaceuticals price target raised to $600 from $540 at Oppenheimer
Citi Analyst forecast on VRTX
Geoff Meacham
Citi
Citi
$575→$585
Buy
35.08%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $585 from $575 at CitiVertex Pharmaceuticals price target raised to $585 from $575 at Citi
Jefferies Analyst forecast on VRTX
Akash Tewari
Jefferies
Jefferies
$580
Buy
33.93%
Upside
Initiated
03/10/26
Vertex Pharmaceuticals initiated with a Buy at JefferiesVertex Pharmaceuticals initiated with a Buy at Jefferies
Morgan Stanley Analyst forecast on VRTX
Terence Flynn
Morgan Stanley
Morgan Stanley
$570→$596
Buy
37.62%
Upside
Assigned
03/10/26
Vertex Pharmaceuticals price target raised to $596 from $570 at Morgan StanleyVertex Pharmaceuticals price target raised to $596 from $570 at Morgan Stanley
TD Cowen Analyst forecast on VRTX
Phil Nadeau
TD Cowen
TD Cowen
$525
Buy
21.23%
Upside
Reiterated
03/10/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and HCA Healthcare (NYSE: HCA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on VRTX
Evan Seigerman
BMO Capital
BMO Capital
$600
Buy
38.55%
Upside
Reiterated
03/27/26
Vertex Pharmaceuticals: Resilient CF Franchise and Advancing Pipeline Support Buy Rating Despite Label Headwinds
William Blair Analyst forecast on VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/26/26
Analysts Conflicted on These Healthcare Names: Vertex Pharmaceuticals (NASDAQ: VRTX), Pacira Pharmaceuticals (NASDAQ: PCRX) and Alnylam Pharma (NASDAQ: ALNY)
Stifel Nicolaus Analyst forecast on VRTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$466
Hold
7.60%
Upside
Assigned
03/25/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Sarepta Therapeutics (NASDAQ: SRPT)
RBC Capital Analyst forecast on VRTX
Brian Abrahams
RBC Capital
RBC Capital
$546→$541
Buy
24.92%
Upside
Reiterated
03/19/26
RBC Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on VRTX
Naz Rahman
Maxim Group
Maxim Group
$575
Buy
32.77%
Upside
Upgraded
03/18/26
Vertex Pharmaceuticals upgraded to Buy from Hold at MaximVertex Pharmaceuticals upgraded to Buy from Hold at Maxim
Bank of America Securities Analyst forecast on VRTX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
03/16/26
Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)
Truist Financial Analyst forecast on VRTX
Joon Lee
Truist Financial
Truist Financial
$490→$525
Buy
21.23%
Upside
Reiterated
03/11/26
Vertex Pharmaceuticals price target raised to $525 from $490 at TruistVertex Pharmaceuticals price target raised to $525 from $490 at Truist
Canaccord Genuity Analyst forecast on VRTX
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$441
Hold
1.83%
Upside
Reiterated
03/11/26
Canaccord Genuity Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
H.C. Wainwright Analyst forecast on VRTX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$591→$641
Buy
48.01%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $641 from $591 at H.C. WainwrightVertex Pharmaceuticals price target raised to $641 from $591 at H.C. Wainwright
Needham Analyst forecast on VRTX
Joseph Stringer
Needham
Needham
$460
Hold
6.22%
Upside
Reiterated
03/10/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Oppenheimer Analyst forecast on VRTX
Jay Olson
Oppenheimer
Oppenheimer
$540→$600
Buy
38.55%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $600 from $540 at OppenheimerVertex Pharmaceuticals price target raised to $600 from $540 at Oppenheimer
Citi Analyst forecast on VRTX
Geoff Meacham
Citi
Citi
$575→$585
Buy
35.08%
Upside
Reiterated
03/10/26
Vertex Pharmaceuticals price target raised to $585 from $575 at CitiVertex Pharmaceuticals price target raised to $585 from $575 at Citi
Jefferies Analyst forecast on VRTX
Akash Tewari
Jefferies
Jefferies
$580
Buy
33.93%
Upside
Initiated
03/10/26
Vertex Pharmaceuticals initiated with a Buy at JefferiesVertex Pharmaceuticals initiated with a Buy at Jefferies
Morgan Stanley Analyst forecast on VRTX
Terence Flynn
Morgan Stanley
Morgan Stanley
$570→$596
Buy
37.62%
Upside
Assigned
03/10/26
Vertex Pharmaceuticals price target raised to $596 from $570 at Morgan StanleyVertex Pharmaceuticals price target raised to $596 from $570 at Morgan Stanley
TD Cowen Analyst forecast on VRTX
Phil Nadeau
TD Cowen
TD Cowen
$525
Buy
21.23%
Upside
Reiterated
03/10/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and HCA Healthcare (NYSE: HCA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
xxx
Success Rate
21/29 ratings generated profit
72%
Average Return
+7.29%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 72.41% of your transactions generating a profit, with an average return of +7.29% per trade.
1 Year
Salveen RichterGoldman Sachs
Success Rate
16/19 ratings generated profit
84%
Average Return
+10.96%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +10.96% per trade.
2 Years
xxx
Success Rate
34/39 ratings generated profit
87%
Average Return
+18.27%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 87.18% of your transactions generating a profit, with an average return of +18.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
0
0
0
0
0
Buy
37
41
47
50
56
Hold
17
15
13
7
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
56
60
57
67
In the current month, VRTX has received 56 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 557.05.
Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $4.47 with a range of $3.67 to $5.23. The previous quarter’s EPS was $5.03. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for VRTX is $4.47 with a range of $3.67 to $5.23. The previous quarter’s EPS was $5.03. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.07B with a range of $2.91B to $3.23B. The previous quarter’s sales results were $3.23B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.
Next quarter’s sales forecast for VRTX is $3.07B with a range of $2.91B to $3.23B. The previous quarter’s sales results were $3.23B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals Inc.’s 12-month average price target is 557.05.
    What is VRTX’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals Inc. has 28.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRTX a Buy, Sell or Hold?
          Vertex Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 21 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Vertex Pharmaceuticals Inc.’s price target?
            The average price target for Vertex Pharmaceuticals Inc. is 557.05. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $641.00 ,the lowest forecast is $441.00. The average price target represents 28.63% Increase from the current price of $433.07.
              What do analysts say about Vertex Pharmaceuticals Inc.?
              Vertex Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.
                How can I buy shares of VRTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.